Drugmaker Eli Lilly warned this week that two of its formulations of insulin would be temporarily out of stock through the beginning of April, citing a “brief delay in manufacturing.” The 10 ...

Ricks said Eli Lilly backs legislation that would impose a $35 per month price cap for insulin covered under private health insurance plans. "We are left in 2023 with a split situation," he said.

Eli Lilly is looking to approach regulators for approval of its once-weekly insulin for type 2 diabetes (T2D) after it proved ...

Drugmaker Eli Lilly says it will cut its insulin prices up to 70% and cap out-of-pocket costs for privately insured consumers at $35 a month.

Eli Lilly cuts the price of insulin, capping drug at $35 per month out-of-pocket. March 1, 2023 10:44 AM ET. By . The Associated Press Enlarge this image.

Eli Lilly, along with Sanofi and Novo Nordisk make up 90% of the US market for insulin. Lilly shares were up 1.3% at $315.30. Some analysts have suggested the company was trying to get out ahead ...

Diabetics can face annual costs of more than $1,000 for insulin they need in order to live, a fee that has been widely criticized as prices have continued to rise.

Drug manufacturer Eli Lilly announced yesterday that it’s implementing multiple price-lowering changes that will reduce out-of-pocket costs for insulin products by up to 70 percent. Insulin has ...

The high costs of insulin made by Lilly and other drug companies — out-of-pocket payments for people on certain high-deductible insurance plans can exceed $1,000 a month, though most patients ...

A Lilly spokeswoman said the current list price for a 10-milliliter vial of the fast-acting, mealtime insulin Humalog is $274.70. That will fall to $66.40. Likewise, she said the same amount of ...

Diabetics can face annual costs of more than $1,000 for insulin they need in order to live, a fee that has been widely criticized as prices have continued to rise.

Diabetics can face annual costs of more than $1,000 for insulin they need in order to live, a fee that has been widely criticized as prices have continued to rise.